CD8A and neoplasm: As seen in Figure 6I–L, compared to untreated tumors, HMP1G NPs treatment resulted in an ≈8.50‐fold increase in the number of tumor‐infiltrating IFNγ+ CTLs (CD3+CD8+IFNγ+) and a threefold increase in the number of tumor‐infiltrating GrzB+ CTL (CD3+CD8+GrzB+), which are essential for CTL‐mediated potent anticancer cytotoxicity and immune activation.[42] Based on the above analysis, it can be concluded that the abundance of effector T cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+) were significantly increased in mouse tumors treated with HMP1G NPs.